Stephen Hanauer News Today

Johnson & Johnson has settled its lawsuit with Amgen regarding the latter company’s Stelara biosimilar, clearing the way for a January 2025 release date in the United States, according to results of a federal court filing. Meanwhile, the rheumatology world awaits the debut of other ustekinumab biosimilars in the market — and what they may portend for patient care moving forward

I have long wondered how the nuclear industry measures and manages risk. I am familiar with risk management systems used by process safety engineers, insurance companies, the airline industry, data/software engineers, etc. Each one employs some sort of risk matrix and performs qualitative and/or quantitative risk analysis by identifying sets of scenarios, their possible costs

A new history reveals that federal regulators consistently assured Americans that the risks of a massive accident were “vanishingly small”—even when they knew they had insufficient evidence to prove it.

Meta-analysis ranks infliximab and others, but experts urge results are not ready for prime time

After the first year postdiagnosis, patients with celiac disease had an almost 4-fold higher risk of IBD, and patients with IBD had more than a 5-fold higher risk of celiac disease.

Intensive treatment for patients with Crohn's disease showed no safety differences compared to the current standard of care, according to a trial published in the journal Gastroenterology.

The biologic was associated with reduced infection risk when compared with anti-TNF agents or tofacitinib in a real-world analysis of nearly 90 million patients.

A new drug improved management of ulcerative colitis, according to a study published in the New England Journal of Medicine.

Despite the increasing use of anti–TNF medications and a low rate of proctectomy, a recent analysis finds no decline in stoma incidence among patients.

This article is a collaboration between MedPage Today and: Patients with inflammatory bowel disease (IBD) who are in remission on combination therapy may withdraw one of their medications -- usually a tumor necrosis factor (TNF) inhibitor -- if they are at low risk and are followed closely, according to a researcher. "The question all our patients have been asking is when they can stop or cut down on therapy if theyre in remission," said Stephen Hanauer, MD, of Northwestern University Fein...